Brinckerhoff Quoted in Law360 About Groundbreaking Patent Decisions
July 17, 2020
Law360
Partner Courtenay Brinckerhoff was quoted in the Law360 article, “These 10 Decisions Remade the Patent Landscape,” where she discussed the implications of Nautilus v. Biosig Instruments.
In this 2014 ruling, the U.S. Supreme Court discarded a Federal Circuit test that made it difficult to invalidate patents as indefinite, bolstering the defense for accused infringers. “When I first started practicing, you wouldn’t even consider that you could invalidate a patent claim based on indefiniteness. Now it’s definitely something that you would look at in every case,” said Brinckerhoff, who described Nautilus as one of a series of rulings that set a “trend of really deeply scrutinizing the validity of patents.
In this 2014 ruling, the U.S. Supreme Court discarded a Federal Circuit test that made it difficult to invalidate patents as indefinite, bolstering the defense for accused infringers. “When I first started practicing, you wouldn’t even consider that you could invalidate a patent claim based on indefiniteness. Now it’s definitely something that you would look at in every case,” said Brinckerhoff, who described Nautilus as one of a series of rulings that set a “trend of really deeply scrutinizing the validity of patents.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."